25 trends tracked about this subject — the full history, oldest to newest below.
An experimental mRNA vaccine targeting KRAS mutations triggered immune responses in 99% of pancreatic cancer patients in recent Phase 2 study results.
Moderna and Merck's mRNA cancer vaccine reduces melanoma recurrence by 42% according to recent coverage.
9 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Health officials approve the first ever mRNA jab as discussions intensify around what adults aged 50 and older need to know about flu shots.
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
A personalized mRNA cancer vaccine developed by Moderna and Merck cuts melanoma recurrence or death risk by 42%.
9 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
New developments in personalized mRNA cancer vaccines show promise for melanoma and breast cancer, though hurdles in public perception remain.
Advances in personalized mRNA vaccines are showing promise in treating melanoma, though experts warn that misinformation may hinder their adoption.
8 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
The US has seen the launch of Moderna's mFlusiva, the first approved mRNA flu vaccine designed for specific older adult populations.
Moderna's first mRNA flu vaccine has received FDA approval and is now available for older adults ahead of the 2026 flu season.
Moderna and Merck trial data sparks debate over whether a personalized medicine revolution is beginning.
Health coverage highlights FDA approval of Moderna's new mRNA flu vaccine and emerging studies on broader antibody responses.
Recent studies link the shingles vaccine to significant reductions in dementia and cardiovascular disease risks.
The FDA has approved Moderna's mRNA-based flu vaccine, marking a shift in immunization technology for older adults.
Recent trial results for an mRNA vaccine developed by Moderna point toward a potential shift in future cancer care.
Moderna shares double following clinical trial results for a personalized mRNA melanoma vaccine developed with Merck.
Merck and Moderna’s melanoma vaccine hits key survival milestones, sending Moderna's stock soaring.
Moderna stock surges after a partnered melanoma vaccine developed with Merck successfully reduced cancer recurrence in a large-scale clinical trial.
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
1 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
The first mRNA-based flu vaccine has been approved in the US, specifically targeting adults aged 50 and over for improved effectiveness.
3 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
The U.S. has approved the first-ever mRNA flu vaccine from Moderna, though concerns over side effects may impact public adoption.